CLINICAL_TRIALS
trial_result
· 2022-06-27
Clinical Trial Update: A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I) [Phase 3]
Summary
Phase 3 trial of deflazacort (Emflaza) in LGMD2I (Limb-Girdle Muscular Dystrophy type 2I) was terminated; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: PTC Therapeutics | Conditions: Limb-Girdle Muscular Dystrophy | Phase 3 | Status: TERMINATED | Results posted: 2022-06-27